Warnex Inc.'s Medical Laboratories Division Obtains ISO 15189 Accreditation

LAVAL, QUEBEC--(Marketwire - June 29, 2009) - Warnex Inc. (TSX: WNX) announced today that its Medical Laboratories division has obtained ISO 15189:2007 accreditation by the Standards Council of Canada (SCC). This accreditation is an international standard for quality management systems for medical testing laboratories. Warnex Medical Laboratories is only the second private laboratory in Canada to obtain this accreditation.

“We are pleased and proud to have received this second ISO accreditation for our Medical Laboratories division, demonstrating once again our commitment to the highest standards of quality,” said Mark Busgang, President and CEO of Warnex. “We place great importance not only on the quality of our specialized lab services, but also on their continuous improvement. To this end, our dedicated staff worked diligently to achieve ISO 15189 accreditation and continues to expend efforts towards expanding our portfolio of specialized medical testing services.”

The ISO 15189 standard addresses the quality management system of medical laboratories to better serve the needs of both patients and clinical personnel responsible for the care of those patients. The standard encompasses provisions for the pre-analytical phase to the post-analytical phase of medical laboratory services, including advice to users, collection of patient samples, analysis of samples, interpretation of test results, acceptable turnaround times, how testing is to be provided in a medical emergency and the lab’s role in the education and training of health care staff.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex’s analytical services division provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex’s bioanalytical services division specializes in bioequivalence and bioavailability studies for clinical trials. Warnex’s medical laboratories division focuses on genetic and biochemical testing for the healthcare industry and has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, government regulations, laboratory facilities, suppliers, employees, key customers and business partners, foreign currency risk, credit risk, liquidity risk, volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex’s most recent Management’s Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.